文献速递妇科生殖医学

卵巢囊肿切除术后激素治疗预防子宫内膜异位囊肿复发的系统综述与网络荟萃分析

Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis.
PubMed 文献 · BJOG · 2020-07-14

该系统综述与网络荟萃分析比较了不同激素方案预防保守手术后子宫内膜异位囊肿复发的疗效。纳入6项随机对照试验(675例)和16项队列研究(3089例)。随机对照试验的网络荟萃分析未发现激素治疗有效的证据,与队列研究证据相矛盾,后者显示口服避孕药和孕激素方案尤其长期治疗有保护作用。

要点

  • 随机对照试验网络荟萃分析显示,与期待管理相比,所有激素方案复发风险降低均未达统计学显著。
  • 队列研究网络荟萃分析显示,左炔诺孕酮宫内缓释系统、地诺孕素、连续口服避孕药、促性腺激素释放激素激动剂联合口服避孕药及周期性口服避孕药复发风险显著低于期待管理。
  • 左炔诺孕酮宫内缓释系统排序最高,其次为地诺孕素和促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统。

核心结论

  • 随机对照试验的网络荟萃分析中,没有证据支持术后激素治疗预防子宫内膜异位囊肿复发。
  • 这与队列研究证据相矛盾,队列研究发现口服避孕药和孕激素方案尤其长期治疗有保护作用。
  • 仍需要这些药物的大规模随机对照试验。

研究设计与样本

  • 系统综述与网络荟萃分析,检索MEDLINE和Scopus数据库至2020年1月。
  • 纳入比较任意一对干预措施对子宫内膜异位囊肿复发影响的随机对照试验或队列研究。
  • 纳入6项随机对照试验(675例患者)和16项队列研究(3089例患者)。
  • 由两名评价者独立提取数据,使用网络荟萃分析估计相对治疗效果并按降序排序。

主要发现

  • 涉及期待管理、周期性口服避孕药、连续口服避孕药、促性腺激素释放激素激动剂和促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统的随机对照试验网络荟萃分析显示,所有激素方案相比期待管理的子宫内膜异位囊肿复发风险降低均未达统计学显著。
  • 涉及期待管理、周期性口服避孕药、连续口服避孕药、促性腺激素释放激素激动剂、地诺孕素、左炔诺孕酮宫内缓释系统、促性腺激素释放激素激动剂联合口服避孕药和促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统的队列研究网络荟萃分析表明,左炔诺孕酮宫内缓释系统、地诺孕素、连续口服避孕药、促性腺激素释放激素激动剂联合口服避孕药和周期性口服避孕药相比期待管理的子宫内膜异位囊肿复发风险显著更低。
  • 左炔诺孕酮宫内缓释系统排序最高,其次为地诺孕素和促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统。
  • 长期使用激素治疗(口服避孕药或孕激素)相比期待治疗的子宫内膜异位囊肿复发风险显著更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随机对照试验的网络荟萃分析与队列研究证据相矛盾。
  • 仍需要这些药物的大规模随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of hormonal regimens for the prevention of endometrioma recurrence in women who have undergone conservative surgery is still controversial. OBJECTIVE: To compare the efficacy of different hormonal regimens in this context and to rank them. SEARCH STRATEGY: MEDLINE and Scopus databases were searched through January 2020. SELECTION CRITERIA: Randomised controlled trials (RCTs) or cohorts, comparing the effect of any pair of interventions (i.e. cyclic oral contraceptives [OC], continuous OC, gonadotropin-releasing hormone agonist [GnRHa], dienogest [DNG], levonorgestrel-releasing intrauterine system [LNG-IUS] and expectant management) on endometrioma recurrence were selected. DATA COLLECTION AND ANALYSIS: Data were independently extracted by two reviewers. Relative treatment effects were estimated using network meta-analysis (NMA) and ranked in descending order. MAIN RESULTS: Six RCTs (675 patients) and 16 cohorts (3089 patients) were included. NMA of the RCTs involving expectant management, cyclic OC, continuous OC, GnRHa and GnRHa + LNG-IUS, showed that all hormonal regimens had a nonsignificant lower risk of endometrioma recurrence compared with expectant management. NMA of the cohorts involving expectant, cyclic OC, continuous OC, GnRHa, DNG, LNG-IUS, GnRHa + OC, and GnRHa + LNG-IUS indicated that LNG-IUS, DNG, continuous OC, GnRHa + OC and cyclic OC had a significantly lower risk of endometrioma recurrence than expectant management. LNG-IUS was ranked highest, followed by DNG and GnRHa + LNG-IUS. Long-term use of hormonal treatment either OC or progestin had a significantly lower risk of endometrioma recurrence than expectant treatment. CONCLUSION: In the NMA of RCTs, there was no evidence supporting hormonal treatment for postoperative prevention of endometrioma recurrence. This was at odds with the cohort evidence, which found the protective effect of OC and progestin regimens, especially long-term treatment. Large-scale RCTs of these agents are still required. TWEETABLE ABSTRACT: Hormonal regimens given as long-term treatment tend to reduce risk of endometrioma recurrence after conservative surgery.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wattanayingcharoenchai R, Rattanasiri S, Charakorn C, et al. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG. 2020. PMID: 32558987. doi:10.1111/1471-0528.16366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。